Cortrophin Gel repository corticotropin injection Updated Nov 16
Cortrophin Gel is already approved and commercialized with no pending regulatory binary. The key near-term catalysts are commercial execution metrics: Q4 2026 Cortrophin revenue (expected early Feb 2027) will show whether the specialty pharmacy capacity constraints that slowed Q3 conversion have resolved, and whether the gout sales force expansion is gaining traction. The Egetis/EMCITATE acquisition acceptance period (Nov 20-Dec 18, 2026) is a separate corporate event that could affect ANIP's balance sheet and rare disease strategy.
- Cortrophin Gel is ANIP's largest and fastest-growing product: Q3 2026 revenue of $138.7M was up 36% YoY and 18% QoQ, with full-year 2026 guidance of $480M-$500M (38-44% YoY growth).
- The drug is the only FDA-approved purified corticotropin product, competing in a market with limited alternatives (primarily Mallinckrodt's Acthar Gel), giving ANIP pricing power and a sticky chronic-use patient base.
- ANI is expanding into the acute gout indication with a dedicated sales force, which could open a large new patient population and drive further growth.
- Cortrophin Gel revenue guidance was cut in August 2026 from $540M-$575M to $520M-$540M, and then narrowed further to $480M-$500M by November 2026, signaling demand or conversion headwinds.
- Q3 2026 revenue conversion was slower than expected due to specialty pharmacy capacity constraints, suggesting operational bottlenecks that could persist.
- The drug faces potential competition from Acthar Gel (Mallinckrodt), and any generic or biosimilar entry could erode pricing.